Trying to decide which health insurance policy to choose? Now there’s an interactive tool to help you choose an insurance policy for the open enrollment period.
Read More »Author: NCHR Author
Anthem Says Will Not Cover Sarepta’s Approved Duchenne Drug
Reuters, October 7, 2016. To keep health insurance affordable, companies need to ensure that they are paying for safe and effective treatments, said Diana Zuckerman, president of non-profit organization National Center for Health Research. “When FDA fails to ensure those standards, then ‘FDA approval’ is no longer a gold standard that insurance companies can rely on,” she said.
Read More »NCHR Position Regarding Anthem Decision that Exondys 51 is Experimental
October 7, 2016. We continue to strongly urge Sarepta to do the studies needed to support their claims that patients benefit from Exondys 51, and in the meanwhile Sarepta should ensure that patients in those studies receive the treatment for free.
Read More »Anthem Declines to Cover Sarepta Drug for Duchenne, Citing Doubts over Data
STAT News, October 7, 2016. One of the nation’s largest health insurers has decided not to cover a controversial Duchenne muscular dystrophy drug because its FDA approval was not based on scientific evidence that it works. This is what NCHR predicted would happen.
Read More »Obama Extends Controversial Program for Rare Pediatric Drugs
STAT News, September 30, 2016. Friday, President Barack Obama signed into law a bill that will briefly extend a voucher program that rewards drug makers for rare pediatric medicines.
Read More »